Session » Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Clinical Aspects and Therapeutics Poster III

Date: Tuesday, November 7, 2017

Time: 9:00AM-11:00AM

Meeting: 2017 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 2680

Analysis of Prognostic Determinants of Scleroderma-Associated Pulmonary Arterial Hypertension and Idiopathic Pulmonary Arterial Hypertension

9:00AM-11:00AM: Abstract Number: 2664

Anti-SSA (Ro52/Ro60) and SSB Autoantibodies in Patients with Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 2671

Bosentan in Scleroderma Renal Crisis: A National Open Label Prospective Study

9:00AM-11:00AM: Abstract Number: 2663

Changes in Disability over Time, and Their Relationship with Degree of Skin Thickening, in Patients with Limited and Diffuse Cutaneous Systemic Sclerosis: A Retrospective Cohort Study

9:00AM-11:00AM: Abstract Number: 2687

Characteristic of Pulmonary Arterial Hypertension in Patients with Anti-U1RNP Antibody-Positive-Connective Tissue Diseases Is Determined By the Underlying Disease Rather Than Autoantibody Profile

9:00AM-11:00AM: Abstract Number: 2661

Clinical Impact of Selenium and Vitamin C Deficiency in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 2688

Collagen Metabolite Biomarker Levels Are Associated with the Amount of Fibrosis in Internal Organs in Systemic Sclerosis Patients

9:00AM-11:00AM: Abstract Number: 2678

Comparison of Scleroderma Associated Isolated Pulmonary Arterial Hypertension and Pulmonary Hypertension with Concomitant Interstitial Lung Disease

9:00AM-11:00AM: Abstract Number: 2682

Correlation between Capillaroscopic Patterns of Nailfold Microangiopathy and Three Different Methods to Assess Dermal Thickness in Systemic Sclerosis Patients

9:00AM-11:00AM: Abstract Number: 2660

Endothelin-1 and Interleukin-6 Serum Levels Are Associated with More Severe Vasculopathy in Patients  with Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 2681

Epidemiology and Survival of Systemic Sclerosis-Systemic Lupus Erythematosus Overlap Syndrome

9:00AM-11:00AM: Abstract Number: 2683

Factors Associated with Disease Progression in Early-Diagnosed Pulmonary Arterial Hypertension Associated with Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 2677

Impact of Rheumatologic Evaluation and Serologic Testing on Patients with Fibrotic Interstitial Lung Disease: A Single Center Retrospective Experience

9:00AM-11:00AM: Abstract Number: 2686

In Established Pulmonary Arterial Hypertension the Follow-up Cardiac Catheterization-Derived Pulmonary Artery Systolic Pressure and Vascular Resistence May be Predicted By Echocardiography- a Longitudinal Study in Two Connective Tissue Disease Cohorts

9:00AM-11:00AM: Abstract Number: 2691

Increased Circulating Cadherin-11 Levels in Patients with Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 2675

Lung Transplant Trends in Patients’ with Systemic Sclerosis Using UNOS (United Network Organ Sharing) Database from 2000-2014

9:00AM-11:00AM: Abstract Number: 2669

Microvascular Flow Assessed By Dynamic Optical Coherence Tomography: First Non-Invasive Quantitative Outcome Measure of Microvascular Disease in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 2665

Mortality in an Early Diffuse Cutaneous Systemic Sclerosis Cohort—Data from the Prospective Registry for Early Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 2679

Mortality Is Increased in Scleroderma Associated Pulmonary Arterial Hypertension Patients with Younger Age, Lower Systolic Blood Pressure, and Lower Cardiac Index, but Not in Idiopathic Pulmonary Arterial Hypertension

9:00AM-11:00AM: Abstract Number: 2672

Perceived Barriers to Mental Health Care Among Patients with Systemic Sclerosis: A Qualitative Study

9:00AM-11:00AM: Abstract Number: 2690

Plasma D-Dimer Levels Are More Frequently Elevated in Limited Than Diffuse Cutaneous Systemic Sclerosis but Do Not Reflect Disease Duration or Vasculopathy

9:00AM-11:00AM: Abstract Number: 2673

Real-Life Treatment Strategies for Systemic Sclerosis According to Experts

9:00AM-11:00AM: Abstract Number: 2676

Reduction of Dlco and FVC in Patients with GERD and Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 2684

Regional and Whole Gut Transit Times in Patients with Systemic Sclerosis Using the Wireless Motility Capsule

9:00AM-11:00AM: Abstract Number: 2668

Responsiveness of University of California Los Angeles Scleroderma Clinical Trial Consortium (GIT2.0) and Intestinal Visual Analogue Scale to Change in Systemic Sclerosis Patients

9:00AM-11:00AM: Abstract Number: 2685

Sensitivity and Specificity of YKL-40 for the Presence of Pulmonary Arterial Hypertension in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 2674

The Association between the Extent of Skin Thickness and Organ Involvement, Function and Quality of Life in Early Diffuse Cutaneous Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 2667

The Association between Two Non-Invasive Methods for the Assessment of Severity of Gastrointestinal Involvement and Malnutrition in Systemic Sclerosis: Self-Reported Questionnaires and Nail Fold Video-Capillaroscopy

9:00AM-11:00AM: Abstract Number: 2666

The Clinical Utility of Flow-Mediated Dilation in Systemic Sclerosis Digital Ulcer Assessment

9:00AM-11:00AM: Abstract Number: 2662

The EULAR Systemic Sclerosis Impact of Disease (ScleroID) Score – a New Patient-Reported Outcome Measure for Patients with Systemic Sclerosis – Preliminary Results from the Ongoing Validation Study

9:00AM-11:00AM: Abstract Number: 2670

Trigeminal Neuralgia in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 2689

Troponinemia Independently Associates with Mortality in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 2692

Vitamin D Deficiency in Systemic Sclerosis Patients: Relations with Multiple Clinical Parameters and Standard Treatment

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].